Peptomyc Raises €5.7M for MYC Cancer Drug Development

Peptomyc, a clinical-stage biopharmaceutical company, has finalized a significant funding round, bringing in €5.7 million. This capital infusion is earmarked to propel the development of its novel MYC-targeting oncology drug, OMO-103, through its ongoing clinical trials and prepare for later-stage development and potential pharmaceutical partnerships.

The latest tranche of investment includes a €0.7 million contribution from the Institut Català de Finances (ICF), marking the first deployment from its new Lidera Transferència en Salut fund. This public sector backing complements earlier investments from a consortium of specialized life science investors. The round initially closed in February 2026 with €5 million, led by Alta Life Sciences Spain I, advised by Asabys Partners, and Aurora Science. Other key participants in the initial close included the EIC Fund, Laudecum, and CDTI Innovación via its SICC Innvierte vehicle.

This diversified investor base now unites private venture capital firms focused on life sciences with prominent public co-investors at Catalan, Spanish, and European levels. The strategic alignment of these entities underscores the potential of Peptomyc's therapeutic approach. The company is focused on completing three active clinical studies for OMO-103, a pioneering direct pan-MYC inhibitor that has shown promise in early clinical settings, as detailed in a 2024 publication in Nature Medicine. The MYC oncogene pathway has long been a challenging target in cancer research, making Peptomyc's progress particularly noteworthy.

Funds will also support the scale-up of manufacturing processes necessary for subsequent development phases. Furthermore, Peptomyc is actively engaging with potential pharmaceutical collaborators to explore strategic alliances. The company recently strengthened its leadership team by appointing Dr. Stephan Braun as Chief Medical Officer (CMO) and anticipates presenting Phase 1b data for OMO-103 in first-line metastatic pancreatic cancer before the end of 2026.

Jesús Martín García, CEO of Peptomyc, highlighted the importance of the funding, stating, “Securing this round with public co-investment from ICF, alongside investors committed to advancing MYC inhibition from bench to bedside, is a strong validation of our science and team. We now possess the resources to complete our ongoing studies and generate the clinical and translational evidence essential for OMO-103’s next development stage.”

The Lidera Transferència en Salut fund, managed by ICF, is dedicated to supporting health and life science projects originating from Catalan research institutions. With a total of €60 million, including €50 million from the Generalitat de Catalunya and €10 million from ICF, the fund aims to de-risk early-stage advanced therapies, making them attractive for private investment. This initiative reflects a growing trend of public-private partnerships aimed at fostering innovation within the European life sciences sector, a market segment experiencing robust growth driven by advancements in targeted therapies and personalized medicine.